Chinese VC to inject $30M into Pluristem Therapeutics

China flag

Israeli micro-cap biotech Pluristem Therapeutics ($PSTI) was up by more than 11% premarket this morning on the news that it is set to gain a $30 million boost through a China-based venture firm.

The cash boost will come from the China-based co Innovative Medical Management, a part of Zheshang Venture Capital (ZSVC).

This firm has around ¥30 billion ($4.45 billion) under management through more than 30 venture capital, private equity, angel, and buyout funds, according to the biotech’s statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Drilling down into the details, around 16.9 million shares of Pluristem common stock will be sold at $1.77 per share. As of yesterday, it was trading at $1.52.

Pluristem will also issue to Innovative Medical around 4.4 million warrants to purchase shares of its common stock alongside an exercise price of $2.50 per warrant, exercisable for 5 years. The co also gets a seat at the Pluristem board for its troubles.

Shareholders from Innovative Medical still have to sign off on the deal, which is expected to happen by mid-November.

Pluristem’s business is based upon a process of expanding cells from full-term human placentas in bioreactors.

When the cells are given to a patient, they are thought to reverse tissue damage by releasing cytokines, chemokines and growth factors. The idea has yet to be tested in late-phase trials, with an ongoing Phase II in patients with intermittent claudication the most advanced program.

Last year it was given a spot on the European Medicines Agency's adaptive pathways pilot project that aimed to help reduce the time it could take to bring its PLX cell program in critical limb ischemia to market in a subpopulation.

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.